Vericiguat in Stable HFrEF Patients: No Improvement in Composite Endpoint but Significant Reduction in Cardiovascular and All-Cause Mortality – Insights from the VICTOR Trial
Posted inCardiology Clinical Updates news Specialties

Vericiguat in Stable HFrEF Patients: No Improvement in Composite Endpoint but Significant Reduction in Cardiovascular and All-Cause Mortality – Insights from the VICTOR Trial

The VICTOR trial in stable HFrEF patients shows vericiguat does not significantly reduce the composite of cardiovascular death or heart failure hospitalization but lowers cardiovascular and all-cause mortality, highlighting its potential for mortality risk reduction.